Sign in Subscribe

left-sided

A collection of 4 issues

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not

CRC Research Finding

Skip to content The CRC Digest ◇ Tumor Sidedness Affects Liquid Biopsy Interpretation in Metastatic CRC Right-sided and left-sided tumors exhibit distinct molecular profiles, and researchers found that tumor sidedness impacts circulating RAS mutational status and interpretation of liquid biopsy results. (Molecular Diagnosis & Therapy) This content is informational only and

CRC Research Finding

Skip to content The CRC Digest ◇ Left-sided and right-sided colorectal cancers show distinct molecular drivers Multi-omics analysis of 80 CRC patients revealed that left-sided tumors are predominantly driven by chromosomal instability, while right-sided cancers are primarily linked to microsatellite instability. (MedComm) This content is informational only and does not constitute

RAS/BRAF wild-type patients: Maintenance strategies compared

Skip to content The CRC Digest RAS/BRAF wild-type patients: Maintenance strategies compared Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute) This content is informational only and does not constitute medical advice. Always